羟基喜树碱联合化疗治疗卵巢癌临床分析

Adjuvant Therapeutic Effect of Hydroxycamptothecin on Ovarian Cancer

目的探讨羟基喜树碱对卵巢癌的辅助治疗作用及效果。方法60例晚期卵巢癌患者,随机分为治疗组及对照组,每组30例,术前术后规律化疗,对照组给予标准(CAP)化疗方案,治疗组给予(CAP)+羟基喜树碱化疗方案,对比两组患者术前缓解率,手术切除情况及预后情况。结果治疗组手术前症状缓解率为86.7%,肿块缩小28mm,手术切除率90.0%,三年生存率40%。对照组中手术前症状缓解率为60.0%,肿块缩小13mm,手术切除率76.7%,三年生存率36.7%,治疗组同对照组间症状缓解率,肿块缩小程度,手术切除率有显著差异。结论羟基喜树碱辅助治疗卵巢癌,能增加手术的切除率,改善预后,提高疗效。

Objective To investigate the adjuvant therapeutic effect of hydroxycamptothecin （HCPT） on ovarian cancer. Methods Sixty advanced ovarian cancer patients were randomly divided into experimental group and control group,with 30 patients in each. The patients in both groups received chemotherapy with cyclophosphamide, adriamycin and platinol（CAP）, and besides, the patients of experimental group recieved the treatment with HCPT, and the preoperative remission rate and complete resection of tumor and prognosis in patients of two groups were observed. Results The preoperative remission rate of experimental group was 86.7% and the complete resection of tumor was 90.0%,the tumor diameter showed a 28mm reduction,and a three-year survival rate was 40%,and those of control group were 60% ,76.7% and 36.7% and a 13mm reduction,respectively. There was a significant difference in the preoperative remission rate and complete resection of tumor and tumor diameter decrease between the two groups. Conclusion Chemotherapy with HCPT as an adjuvant therapy in ovarian cancer can obtain good therapeutic efficacy,elevate the surgical resection rate and improve prognosis,raising therapeutic efficacy.